This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
What will unrestricted access to Medicinal Cannabis look like in Australia? A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals Right now in Australia, access to Cannabis-based treatments is heavily restricted. kg of CBD and 163.7
See the WhitePaper below. The Canadian Hemp Trade Alliance (CHTA) and Canadian Health Food Association (CHTA) distributed the attached News Release and WhitePaper on 8May2019 asking the Government of Canada to revise their policy on CBD. 2019-05-08-CHTA-CHFA-CBD-White-Paper-Press-Release-(Final).
The whitepaper outlines the challenges for the insurance industry in regulating cannabis and it establishes a guideline, or a starting point, for state insurance regulations. THE WHITEPAPER. If there’s one take home from the paper for regulators to consider, it’s that there’s much to be done, according to Lara. “The
Indeed, there is a danger that federal legalization, done incorrectly, could produce outcomes even more adverse than the status quo wherein consumers and patients in states where marijuana is legal are generally able to access the marijuana they need.
Those policy areas include public safety concerns, youth prevention, minority access to the industry, and national standards on product testing and pesticides. The group plans to compile data and research, and to release whitepapers on these policy issues that can be used to inform lawmakers.
LOS ANGELES–(BUSINESS WIRE)–Jan 9, 2020– Oasis Intelligence officially launched today, offering brand marketers in the cannabis and hemp industry, as well as related sectors, a much needed tool: unprecedented access to consumer insights at scale. Simple access to cannabis is the initial driver of sales.
We have written a set of seven whitepapers that are available to the public to review. The subjects covered in the whitepapers are: Brief Background of Legal Cannabis Regulation in California. You can access the whitepapers to view here. Our understanding is that many of our peers charge $5 – $7.5K
The full version of the whitepaper is available for free to Cannabiz Media License Database subscribers. Existing Cannabis License Holders : Licensees can access information in the report to gauge the footprint of software vendors in order to make critical business decisions. a state’s potential addressable market) in 2020.
Yet, more than half of the people in the least developed countries lack access to electricity. The second phase of cerVIA™ clinical trials in India is complete, with whitepaper submissions underway. Digital Accessibility Compliance – More than 1 billion people live with a disability.
Indeed, one cannabis testing laboratory released a whitepaper earlier this year claiming that cannabis pesticide contamination is a serious issue in Washington, especially for concentrates that, when tested on an “ off the shelf ” basis in 2018, had pesticide failure rate as high as 40%.
a WA licensed cannabis testing laboratory, in a whitepaper released in February, the issue of pesticide contamination in cannabis products in the state is serious. The Board’s consumer safety concern is indeed a legitimate one as recreational use cannabis producers were previously not required to test for pesticides at all.
The NCIA and Arcview Group report authors identify five areas where the gender gap must close in order for businesses to achieve parity: Capital access. The “Gender Parity in the C-Suite” whitepaper from NCIA and The Arcview Group identifies seven factors that strongly contribute to the gender gap in the cannabis industry: 1.
This whitepaper offers a primer to the complex and confusing global cannabis industry as it stands today. They don’t want to disallow access to the only thing that may stop epileptic seizures in children or is part of a patient’s treatment plan.” People are not enthused about prohibiting medical care.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content